FOLH1 and neuroendocrine neoplasm: Additionally, the widespread availability of 68Ga has resulted in its increasing use as a diagnostic radionuclide partner for nuclear medicine theranostics, highlighted by prostate cancer clinical trials using [68Ga]Ga-PSMA compounds as a diagnostic imaging agent for [177Lu]Lu-PSMA or [225Ac]Ac-PSMA therapy (Kratochwil et al. 2016), and [68Ga]Ga-DOTATATE used to track [177Lu]Lu-DOTATATE or [225Ac]Ac-DOTATATE therapy of neuroendocrine tumors (Bal et al. 2021).